(NASDAQ: PSTV) Plus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.
Plus Therapeutics's earnings in 2025 is -$12,978,000.On average, 2 Wall Street analysts forecast PSTV's earnings for 2025 to be -$11,389,749, with the lowest PSTV earnings forecast at -$16,999,626, and the highest PSTV earnings forecast at -$5,779,873. On average, 2 Wall Street analysts forecast PSTV's earnings for 2026 to be -$12,834,718, with the lowest PSTV earnings forecast at -$16,659,633, and the highest PSTV earnings forecast at -$9,009,802.
In 2027, PSTV is forecast to generate -$8,329,817 in earnings, with the lowest earnings forecast at -$8,329,817 and the highest earnings forecast at -$8,329,817.